Contact: Cindy Starr
Early results of a Phase I clinical trial that is available at only three centers in the world, including the UC Brain Tumor Center, were reported at the American Association for Cancer Research’s annual meeting in San Diego.
The Phase I trial is for patients who have a subtype of malignant glioma that expresses the EGFRvIII mutation and whose cancer has returned. Dr. Mark Rosenthal, Director of Medical Oncology at Royal Melbourne Hospital, presented early data from the study at a conference section that highlighted new drugs in development.
Results of the drug, AMG 595, manufactured by Amgen, are sufficiently promising that research will expand in the near future, said Dr. Richard Curry, a neuro-oncologist with the UC Brain Tumor Center. One-third of all patients with malignant glioma express the EGFRvIII mutation.
“The trial is moving forward,” Dr. Curry said. “The availability of this trial in Cincinnati offers a unique opportunity to patients. Individuals who have undergone a previous treatment that targets EGFR VIII may still be able to enroll in this trial if their tumor returns in the future.”